BRIEF-Rani Therapeutics Announces Preclinical Data Demonstrating Bioequivalence Of RT-114, A GLP-1/GLP-2 Dual Agonist (PG-102) Delivered Orally Via The RaniPill Capsule, To Subcutaneously Administered PG-102

Reuters
27 Mar
BRIEF-Rani <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Announces Preclinical Data Demonstrating Bioequivalence Of RT-114, A GLP-1/GLP-2 Dual Agonist (PG-102) Delivered Orally Via The RaniPill Capsule, To Subcutaneously Administered PG-102

March 26 (Reuters) - Rani Therapeutics Holdings Inc RANI.O:

  • RANI THERAPEUTICS ANNOUNCES PRECLINICAL DATA DEMONSTRATING BIOEQUIVALENCE OF RT-114, A GLP-1/GLP-2 DUAL AGONIST (PG-102) DELIVERED ORALLY VIA THE RANIPILL® CAPSULE, TO SUBCUTANEOUSLY ADMINISTERED PG-102

  • RANI THERAPEUTICS HOLDINGS: PHASE 1 CLINICAL STUDY FOR RT-114 FOR TREATMENT OF OBESITY EXPECTED TO INITIATE IN MID- 2025

Source text: ID:nGNX8h90rs

Further company coverage: RANI.O

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10